Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 22, 2019

View Archived Issues

FDA accepts IND application for ST-920 gene therapy candidate for Fabry disease

Gamida Cell presents clinical data from the NAM-NK and NiCord programs

Foresee reports topline phase III data on FP LMIS for prostate cancer

Transcriptional pathways behind the enhanced bactericidal and lysosomal properties of MPB

Ultragenyx presents positive 24-week data from first cohort of phase I/II study of DTX-401

Guangdong Zhongsheng Pharmaceutical initiates two phase I trials in patients with solid tumors

Nonmyeloablative conditioning vs. head-shielded irradiation to study brain tumor-immune interaction

Development of a novel quadruple agonist to treat nonalcoholic steatohepatitis and fibrosis

Imarikiren improves albuminuria in patients with type 2 diabetes

The European Commission grants approval for Besremi for the treatment of polycythemia vera

Abbisko Therapeutics divulges new FGFR4 inhibitors

Alphala presents new compounds for cancer

CCR5 receptor has role in stroke recovery

Bristol-Myers Squibb identifies TLR7/8/9 antagonists

Morphic Therapeutic and Janssen to collaborate on integrin therapeutics

Humira becomes the first treatment in Japan to be approved for hidradenitis suppurativa

Theravance Biopharma discloses JAK3 inhibitors

Agios Pharmaceuticals initiates phase I study of AG-636 in advanced lymphoma

Calithera initiates phase I study of the arginase inhibitor CB-280

Zeno Royalties & Milestones divulges WEE1hu inhibitors

Phase II study of OPNT-001 in bulimia nervosa does not meet primary endpoint

DEGS1 loss seen to cause hypomyelinating leukodystrophy

Durable responses seen with sacituzumab govitecan in metastatic triple-negative breast cancer

GSE-4 peptide ameliorates oxidative stress, telomere deficiency in ataxia telangiectasia

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026